ProMIS Neurosciences, Inc.

NASDAQ:PMN

Biotechnology

Healthcare
$11.08 -0.14%

-$0.02 today

Market cap
$99.36M
Beta
-0.22
P/E (TTM)
-0.6
EPS (TTM)
-$4.62
52W Low $6.27High $27.40

Volume 0.13M

Average 0.07M

PMN Net Income

Bottom-line profit after all expenses, interest, and taxes.

ProMIS Neurosciences, Inc.NASDAQ: PMN

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income remains negative

Q2 FY2026 net income was -$11.73M, compared with -$10.12M a year earlier. Trailing-twelve-month net income was -$42.23M.

Context

  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly net income holds near -$11.73M or moves back toward the trailing-twelve-month quarterly average of -$10.56M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$11.73M-42.3% QoQ
Last fiscal yearDec 2025
-$39.72M-1529.3% YoY
LTMJun 2026
-$42.23M-401.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.9%——
1 year-1529.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Income history

Mixed currencies · from the income statement

Latest · FY2025
(39.72M) USD
Year-over-year change
-1529.3%

Net Income vs competitors

How PMN compares with its peers on the latest reported figures

  • PMN's LTM Jun 2026 net income of -$42.23M is the 2nd highest of the 4 companies compared; the peer median is -$54.07M.
  • Its year-over-year change of -401.1% is the lowest of 3, against a peer median of -112.6%.
PMN Competitors Peer median
Net Income for PMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EDSAEdesa Biotech, Inc.LTM Mar 2026-$10.44M -78.9%——
PMNProMIS Neurosciences, Inc.LTM Jun 2026-$42.23M -401.1%——
ANLAdlai Nortye Ltd.LTM Jun 2024-$54.07M ——833.1%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$199.48M -146.3%——
Peer median (excluding PMN) -$54.07M-112.6%—833.1%

Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue16.68K0000
Cost of Revenue5.85M010.44M00
Gross Profit(5.84M)0(10.44M)00
Gross Margin-35031.9%————
Research & Development4.95M16.09B7.88M10.64M33.38M
Selling, General & Admin3.31M7.29B6.38M6.19M6.79M
Operating Expenses4.63M23.38B8.45M16.83M40.17M
Depreciation & Amortization45.83K028.04K00
EBITDA(9.33M)(17.78B)(17.81M)2.86M(39.72M)
EBITDA Margin-55923.2%————
Operating Income(10.57M)(23.38B)(18.9M)(16.83M)(40.17M)
Operating Margin-63350.5%————
Interest Income4.73K0000
Interest Expense416.29K282.06M201.39K76.78K0
Other Income / Expenses(1.91M)5.32B1.39M19.61M448.16K
Income Before Tax(12.48M)(18.06B)(17.51M)2.78M(39.72M)
Pre-Tax Margin-74804.2%————
Income Tax Expense00000
Net Income(11.98M)(18.06B)(17.51M)2.78M(39.72M)
Net Margin-71819.3%————
EPS (Basic)(51.77)(60.25)(35.50)2.75(22.61)
EPS (Diluted)(51.77)(60.25)(35.50)2.75(22.61)
Weighted Avg Shares231.42K300.1K491.71K1.04M1.76M
Weighted Avg Shares (Diluted)231.43K300.1K491.71K1.06M1.76M

ProMIS Neurosciences, Inc.

NASDAQ:PMN

Intrinsic Alpha fair value

Locked

Current Price

$11.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.